# Viability of Dugesia dorotocephala Planaria with the Senolytic Drug ARV-825

## TL;DR

This study tests the effect of the drug ARV-825 on planaria and finds that higher concentrations reduce their survival.

## Contribution

The study introduces planaria as a potential model organism for testing the senolytic drug ARV-825.

## Key findings

- Planaria survival decreased from 91.7% at 1µM ARV-825 to 25% at 10µM.
- ARV-825, a PROTAC targeting BRD4, affects planaria viability in a concentration-dependent manner.

## Abstract

Planaria (
Dugesia dorotocephala
) are being utilized as a model system to test the effectiveness of ARV-825. ARV-825 belongs to the drug class proteolysis targeting chimeras (PROTACs), which targets and degrades the protein Bromodomain-containing protein 4 (BRD4) via the proteasome. To examine the impact of ARV-825 on the planaria, planaria viability was tested at different ARV-825 concentrations. This demonstrated a concentration-dependent reduction in viability, 91.7% survival with 1µM ARV-825 reduced to 25% survival in 10 µM ARV-825. This suggests ARV-825 has an effect on
Dugesia dorotocephala
, and indicates that this may be a suitable model organism for studying ARV-825.